Immunovant, Inc.
IMVT
$13.84
-$1.38-9.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -382.71M | -323.01M | -272.55M | -259.34M | -243.45M |
| Total Depreciation and Amortization | 332.00K | 291.00K | 258.00K | 231.00K | 221.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.84M | 46.68M | 44.79M | 42.25M | 40.15M |
| Change in Net Operating Assets | 9.60M | 4.39M | -15.55M | 2.63M | -7.24M |
| Cash from Operations | -324.94M | -271.64M | -243.06M | -214.23M | -210.32M |
| Capital Expenditure | -708.00K | -659.00K | -497.00K | -360.00K | -236.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -708.00K | -659.00K | -497.00K | -360.00K | -236.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.43M | 478.82M | 478.24M | 478.44M | 477.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -6.01M | -6.01M | -6.01M | -6.01M |
| Cash from Financing | 5.43M | 472.81M | 472.22M | 472.43M | 471.12M |
| Foreign Exchange rate Adjustments | 3.97M | 2.51M | 1.38M | 993.00K | -2.23M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -316.25M | 203.01M | 230.05M | 258.83M | 258.33M |